Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

CA1033 Anti-BRCA2 Rabbit pAb

Anti-BRCA2 Rabbit pAb MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: Anti-Breast Cancer Susceptibility Protein

CA1033
  
Purchase on Sigma-Aldrich

Áttekintés

Replacement Information

Kulcsspecifikációk táblázata

Species ReactivityHostAntibody Type
HRbPolyclonal Antibody
Description
Overview

This product has been discontinued.



Recognizes the ~400 kDa BRCA2 protein in MCF-7 and HeLa cells and breast carcinoma.
Catalogue NumberCA1033
Brand Family Calbiochem®
SynonymsAnti-Breast Cancer Susceptibility Protein
Application Data
Detection of human BRCA2 by immunoprecipitation and immunoblotting. Samples: Whole cell lysate from MCF-7 cells (750 µg) (lower panel) and HeLa cells (750 µg) (upper panel). Antibody for IP: Rabbit IgG Control (5µg, lane 1) and Anti-BRCA2 Rabbit pAb (Cat. No. CA1033) (5 µg, lane 2; 10 µg, lane 3; and 15 µg, lane 4). Conditions for immunoblotting: Samples: Whole cell lysate (100 µg) from MCF-7 cells and HeLa cells (lane 5, lower and upper panels, respectively) and BRCA2 IP samples (lanes 1-4). Primary antibody: Anti-BRCA2 (Ab-1) Mouse mAb (2B) (Cat. No. OP95) (2 µg/ml). Detection: chemiluminescence.

Detection of human BRCA2 by staining paraffin sections. Sample: Breast carcinoma tissue (formalin-fixed, paraffin-embedded, heat-pretreated in 10 mM sodium citrate buffer). Primary antibody: Rabbit IgG Control (10 µg/ml, left panel) and Anti-BRCA2 Rabbit pAb (Cat. No. CA1033) (10 µg/ml, right panel). Detection: DAB with methyl green counterstain.
References
ReferencesFirst International Workshop on the Function of BRCA1 and BRCA2. 11-12 September, 1997. Churchill College, Cambridge, UK.
Ludwig, T., et al. 1997. Genes Devel. 11, 122.
Mizuta, R., et al. 1997. Proc. Natl. Acad. Sci. USA 94, 6927.
Rajan, J.V., et al. 1997. Dev. Biol. 184, 385.
Sharan, S.K., et al. 1997. Nature 386, 804.
Suzuki, A., et al. 1997. Genes Devel. 11, 1242.
Canon-Albright, L.A. and Skolnick, M.H. 1996. Semin. Oncol. 23, 1.
Goggins, M., et al. 1996. Cancer Res. 56, 5360.
Rajan, J.V., et al. 1996. Proc. Natl. Acad. Sci. USA 93, 13078.
Spillman, M.A. and Bowcock, A.M. 1996. Oncogene 13, 1639.
Stratton, M.R. 1996. Hum. Mol. Genet. 5, 1515.
Tavtigian, S.V., et al. 1996. Nat. Genet. 12, 333.
Vaughn, J.P., et al. 1996. Cancer Res. 56, 4590.
Wooster, R., et al. 1995. Nature 378, 789.
Product Information
FormLiquid
FormulationIn PBS.
Positive controlMCF-7 and HeLa cells and breast carcinoma
Preservative≤ 0.1% sodium azide
Quality LevelMQ100
Applications
Key Applications Immunoblotting (Western Blotting)
Immunoprecipitation
Paraffin Sections
Application NotesImmunoblotting (2 µg/ml; recombinant protein only)
Paraffin Sections (10 µg/ml, heat-pretreatment required, see comments)
Immunoprecipitation (10 µg per 750 µg total protein)
Application CommentsThis antibody only recognizes recombinant BRCA2 by immunoblotting. For staining paraffin sections, pretreat tissue sections by heating in 10 mM citrate buffer, pH 6.0, for 15 min. Reactivity towards BRCA2 from other species may also occur. BRCA2 protein contains 3418 amino acids with a theoretical isolectric point of 6.3 and a calculated molecular weight of ~376 kDa. However, BRCA2 appears to migrate on SDS/PAGE as a protein with an apparent size of greater than 400 kDa and will co-migrate with the 470 kDa catalytic subunit of DNA-PK. Antibody should be titrated for optimal results in individual systems.
Biological Information
Immunogena recombinant protein consisting of amino acids 3245-3418 of human BRCA2
ImmunogenHuman
HostRabbit
IsotypeIgG
Species Reactivity
  • Human
Antibody TypePolyclonal Antibody
Concentration Label Please refer to vial label for lot-specific concentration
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Shipped with Blue Ice or with Dry Ice
Toxicity Standard Handling
Storage -20°C
Avoid freeze/thaw Avoid freeze/thaw
Do not freeze Ok to freeze
Special InstructionsFollowing initial thaw aliquot and freeze (-20°C).
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Katalógusszám GTIN
CA1033 0

Documentation

Anti-BRCA2 Rabbit pAb MSDS

Title

Safety Data Sheet (SDS) 

Anti-BRCA2 Rabbit pAb Certificates of Analysis

TitleLot Number
CA1033

References

Hivatkozások áttekintése
First International Workshop on the Function of BRCA1 and BRCA2. 11-12 September, 1997. Churchill College, Cambridge, UK.
Ludwig, T., et al. 1997. Genes Devel. 11, 122.
Mizuta, R., et al. 1997. Proc. Natl. Acad. Sci. USA 94, 6927.
Rajan, J.V., et al. 1997. Dev. Biol. 184, 385.
Sharan, S.K., et al. 1997. Nature 386, 804.
Suzuki, A., et al. 1997. Genes Devel. 11, 1242.
Canon-Albright, L.A. and Skolnick, M.H. 1996. Semin. Oncol. 23, 1.
Goggins, M., et al. 1996. Cancer Res. 56, 5360.
Rajan, J.V., et al. 1996. Proc. Natl. Acad. Sci. USA 93, 13078.
Spillman, M.A. and Bowcock, A.M. 1996. Oncogene 13, 1639.
Stratton, M.R. 1996. Hum. Mol. Genet. 5, 1515.
Tavtigian, S.V., et al. 1996. Nat. Genet. 12, 333.
Vaughn, J.P., et al. 1996. Cancer Res. 56, 4590.
Wooster, R., et al. 1995. Nature 378, 789.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision07-October-2008 JSW
SynonymsAnti-Breast Cancer Susceptibility Protein
ApplicationImmunoblotting (2 µg/ml; recombinant protein only)
Paraffin Sections (10 µg/ml, heat-pretreatment required, see comments)
Immunoprecipitation (10 µg per 750 µg total protein)
Application Data
Detection of human BRCA2 by immunoprecipitation and immunoblotting. Samples: Whole cell lysate from MCF-7 cells (750 µg) (lower panel) and HeLa cells (750 µg) (upper panel). Antibody for IP: Rabbit IgG Control (5µg, lane 1) and Anti-BRCA2 Rabbit pAb (Cat. No. CA1033) (5 µg, lane 2; 10 µg, lane 3; and 15 µg, lane 4). Conditions for immunoblotting: Samples: Whole cell lysate (100 µg) from MCF-7 cells and HeLa cells (lane 5, lower and upper panels, respectively) and BRCA2 IP samples (lanes 1-4). Primary antibody: Anti-BRCA2 (Ab-1) Mouse mAb (2B) (Cat. No. OP95) (2 µg/ml). Detection: chemiluminescence.

Detection of human BRCA2 by staining paraffin sections. Sample: Breast carcinoma tissue (formalin-fixed, paraffin-embedded, heat-pretreated in 10 mM sodium citrate buffer). Primary antibody: Rabbit IgG Control (10 µg/ml, left panel) and Anti-BRCA2 Rabbit pAb (Cat. No. CA1033) (10 µg/ml, right panel). Detection: DAB with methyl green counterstain.
DescriptionPurified rabbit polyclonal antibody. Recognizes the ~400 kDa BRCA2 protein.
BackgroundInherited mutations in the BRCA2 gene enhances the risk of familial breast cancer with the neoplasia related to loss of the wild type allele. Human BRCA2 encodes a 3418 amino acid protein with little homology to any known proteins. Transcription of BRCA2 appears to be generally co-ordinately regulated and co-locally expressed with BRCA1 during proliferation and differentiation with low level expression in early G1 and maximal expression occurring during the G1/S transition of the cell cycle. However, BRCA1 and BRCA2 expression is differentially regulated during the development of specific endocrine tissues suggesting a gene-specific response to sex hormones. While loss of BRCA2 is associated with early onset breast cancer, the gene is critical for embryogenesis since nullizygous mice with a deletion of the 5' region of exon 11 arrest development by day 8.5 of gestation. Recently, however, mice carrying homozygous inactivating mutations due to deletion of exon 11 sequences or insertion of selectable markers in the 3' portion of the cDNA have been obtained, albeit with severe growth characteristics including lack of germinal cells, small stature, and skeletal deformities. Loss of BRCA2 expression in embryogenesis does not appear to be due to apoptosis, but proliferation is impaired, perhaps due to enhanced expression of p21WAF1. Although the precise role for BRCA2 is still to be determined, recent studies implicate BRCA2 in DNA repair and recombination processes partly due to association with the Rad51 protein.
HostRabbit
Immunogen speciesHuman
Immunogena recombinant protein consisting of amino acids 3245-3418 of human BRCA2
IsotypeIgG
Specieshuman
Positive controlMCF-7 and HeLa cells and breast carcinoma
FormLiquid
FormulationIn PBS.
Concentration Label Please refer to vial label for lot-specific concentration
Preservative≤ 0.1% sodium azide
CommentsThis antibody only recognizes recombinant BRCA2 by immunoblotting. For staining paraffin sections, pretreat tissue sections by heating in 10 mM citrate buffer, pH 6.0, for 15 min. Reactivity towards BRCA2 from other species may also occur. BRCA2 protein contains 3418 amino acids with a theoretical isolectric point of 6.3 and a calculated molecular weight of ~376 kDa. However, BRCA2 appears to migrate on SDS/PAGE as a protein with an apparent size of greater than 400 kDa and will co-migrate with the 470 kDa catalytic subunit of DNA-PK. Antibody should be titrated for optimal results in individual systems.
Storage Avoid freeze/thaw
-20°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing initial thaw aliquot and freeze (-20°C).
Toxicity Standard Handling
ReferencesFirst International Workshop on the Function of BRCA1 and BRCA2. 11-12 September, 1997. Churchill College, Cambridge, UK.
Ludwig, T., et al. 1997. Genes Devel. 11, 122.
Mizuta, R., et al. 1997. Proc. Natl. Acad. Sci. USA 94, 6927.
Rajan, J.V., et al. 1997. Dev. Biol. 184, 385.
Sharan, S.K., et al. 1997. Nature 386, 804.
Suzuki, A., et al. 1997. Genes Devel. 11, 1242.
Canon-Albright, L.A. and Skolnick, M.H. 1996. Semin. Oncol. 23, 1.
Goggins, M., et al. 1996. Cancer Res. 56, 5360.
Rajan, J.V., et al. 1996. Proc. Natl. Acad. Sci. USA 93, 13078.
Spillman, M.A. and Bowcock, A.M. 1996. Oncogene 13, 1639.
Stratton, M.R. 1996. Hum. Mol. Genet. 5, 1515.
Tavtigian, S.V., et al. 1996. Nat. Genet. 12, 333.
Vaughn, J.P., et al. 1996. Cancer Res. 56, 4590.
Wooster, R., et al. 1995. Nature 378, 789.